Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03970616
Title A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors AVEO Pharmaceuticals, Inc.

hepatocellular carcinoma


Durvalumab + Tivozanib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.